Press Releases

 Partnership Facilitated by Major Investment from Arsenal Capital Partners NEW YORK, July 31, 2019 – Caprion Biosciences (“Caprion”) and HistoGeneX announced today they have agreed to combine their respective businesses. The new partnership creates a global leader in...

MONTREAL, QUEBEC (April 30, 2019) / CNW Telbec / Caprion Biosciences announced today that the company acquired Serametrix Corporation, a specialized provider of immune monitoring services headquartered in Carlsbad, California. Caprion plans to leverage the proprietary...

Serametrix MDSC Assay Being Utilized By Infinity Pharmaceuticals in the First Clinical Study to Prospectively Identify Patients With High Blood Levels of MDSCs First Patient Enrolled in IPI-549 Plus OPDIVO® MDSC-High Cohort in Infinity Pharmaceuticals...

Serametrix gains CLIA certification for MDSC-based blood test for predicting response to immunotherapy in cancer patients SAN DIEGO, California-Sept. 22, 2016. Serametrix has received CLIA approval for MDSC testing in cancer patients, it was announced...

SAN DIEGO, CA, November 19, 2013 -- Serametrix Corporation has announced the launch of an important new blood test for cancer patients. The test measures a patient’s level of circulating Myeloid Derived Suppressor Cells (MDSCs) that are known to decrease...

SAN DIEGO, CA, April 16, 2012 -- Penn State Hershey Children’s Hospital and Serametrix will collaborate on developing a diagnostic test for predicting individual clinical response to a novel immune therapy for brain cancer, it was announced today. The...

Biomarkers May Facilitate Patient Selection For Treatment of Melanoma, Merkel Cell Carcinoma or Cutaneous T-Cell Lymphoma with OMS ElectroImmunotherapy SAN DIEGO, CA, November 16, 2011 -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its...